7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Genetic Predisposition to Disease D020022 24 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Intracranial Hemorrhage, Traumatic D020198 1 associated lipids
Venous Thrombosis D020246 11 associated lipids
Tooth Ankylosis D020254 1 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Lithiasis D020347 2 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Brain Infarction D020520 17 associated lipids
Multiple Sclerosis, Chronic Progressive D020528 3 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Carcinoma, Pancreatic Ductal D021441 6 associated lipids
Coronary Stenosis D023921 6 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Spondylarthritis D025241 1 associated lipids
Spondylarthropathies D025242 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Hearing Loss D034381 3 associated lipids
Mastocytoma D034801 3 associated lipids
Irritable Bowel Syndrome D043183 8 associated lipids
Malnutrition D044342 6 associated lipids
Glucose Metabolism Disorders D044882 3 associated lipids
Scleroderma, Limited D045745 1 associated lipids
Hypertension, Pregnancy-Induced D046110 2 associated lipids
Diabetes Complications D048909 4 associated lipids
Hyperparathyroidism, Primary D049950 1 associated lipids
Hashimoto Disease D050031 1 associated lipids
Dyslipidemias D050171 7 associated lipids
Atherosclerosis D050197 85 associated lipids
Arteriolosclerosis D050379 1 associated lipids
Fractures, Bone D050723 4 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Hypercalciuria D053565 4 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
No-Reflow Phenomenon D054318 2 associated lipids
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative D054438 1 associated lipids
Hyperphosphatemia D054559 1 associated lipids
Osteophyte D054850 2 associated lipids
Chronic Periodontitis D055113 1 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Peri-Implantitis D057873 1 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Peripheral Arterial Disease D058729 7 associated lipids
Osteoporotic Fractures D058866 1 associated lipids
Bisphosphonate-Associated Osteonecrosis of the Jaw D059266 1 associated lipids
Angina, Stable D060050 2 associated lipids
Vascular Calcification D061205 1 associated lipids
Atrial Remodeling D064752 1 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Bénard J [From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? 2000 Bull Cancer pmid:11184451
Yamashita T et al. Retardation in bone resorption after bone marrow ablation in klotho mutant mice. 2000 Endocrinology pmid:10614667
Hofbauer LC et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. 2000 J. Bone Miner. Res. pmid:10646108
Kanzawa M et al. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. 2000 Eur. J. Endocrinol. pmid:10822231
Mukohyama H et al. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. 2000 Biochem. Biophys. Res. Commun. pmid:10777696
Atkins GJ et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. 2000 J. Bone Miner. Res. pmid:10780856
Thompson SW and Tonge D Bone cancer gain without the pain. 2000 Nat. Med. pmid:10802700
Honore P et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. 2000 Nat. Med. pmid:10802707
Onyia JE et al. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. 2000 J. Bone Miner. Res. pmid:10804015
Bateman TA et al. Osteoprotegerin mitigates tail suspension-induced osteopenia. 2000 Bone pmid:10773583
Malyankar UM et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. 2000 J. Biol. Chem. pmid:10811631
Thirunavukkarasu K et al. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. 2000 J. Biol. Chem. pmid:10833509
Aubin JE and Bonnelye E Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. 2000 Medscape Womens Health pmid:10792853
Fata JE et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. 2000 Cell pmid:11051546
Miyamoto N et al. Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. 2000 J. Orthop. Res. pmid:11052502
Kinpara K et al. Osteoclast differentiation factor in human osteosarcoma cell line. 2000 J Immunoassay pmid:11071251
Kong YY et al. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. 2000 Immunol. Today pmid:11071528
Kobayashi Y et al. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. 2000 J. Bone Miner. Res. pmid:11028444
Kaneda T et al. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. 2000 J. Immunol. pmid:11035059
Miyamoto T et al. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. 2000 Blood pmid:11110710
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 Bone pmid:11113385
Takayanagi H et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. 2000 Nature pmid:11117749
Mancini L et al. Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. 2000 Biochem. Biophys. Res. Commun. pmid:11118297
Shalhoub V et al. Characterization of osteoclast precursors in human blood. 2000 Br. J. Haematol. pmid:11122091
Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 J. Bone Miner. Res. pmid:11127193
Sakuma Y et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. 2000 Infect. Immun. pmid:11083800
Riggs BL The mechanisms of estrogen regulation of bone resorption. 2000 J. Clin. Invest. pmid:11086020
Udagawa N et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. 2000 Endocrinology pmid:10965921
Yasuda H [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. 2000 Seikagaku pmid:10967683
Teitelbaum SL Bone resorption by osteoclasts. 2000 Science pmid:10968780
Lacey DL et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. 2000 Am. J. Pathol. pmid:10934148
Quinn JM et al. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. 2000 J. Bone Miner. Res. pmid:10934644
Min H et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. 2000 J. Exp. Med. pmid:10952716
Shiba H et al. Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. 2000 Mech. Ageing Dev. pmid:10958924
López FJ New approaches to the treatment of osteoporosis. 2000 Curr Opin Chem Biol pmid:10959765
Nakashima T et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. 2000 Biochem. Biophys. Res. Commun. pmid:10973797
Itoh K et al. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. 2000 J. Bone Miner. Res. pmid:10976996
Schinke T and Karsenty G Vascular calcification--a passive process in need of inhibitors. 2000 Nephrol. Dial. Transplant. pmid:10978374
Lorenzo J Interactions between immune and bone cells: new insights with many remaining questions. 2000 J. Clin. Invest. pmid:10995785
Teng YT et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. 2000 J. Clin. Invest. pmid:10995794
Børset M et al. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. 2000 Blood pmid:11001907
Hofbauer LC and Heufelder AE Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. 2000 J. Clin. Endocrinol. Metab. pmid:10902778
Rani CS and MacDougall M Dental cells express factors that regulate bone resorption. 2000 Mol. Cell Biol. Res. Commun. pmid:10860862
Tsurukai T et al. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. 2000 J. Bone Miner. Metab. pmid:10874596
Günther T and Schinke T Mouse genetics have uncovered new paradigms in bone biology. 2000 Trends Endocrinol. Metab. pmid:10856921
Huang L et al. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. 2000 Am. J. Pathol. pmid:10702390
Capparelli C et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. 2000 Cancer Res. pmid:10706080
Makhluf HA et al. Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. 2000 Biochem. Biophys. Res. Commun. pmid:10679262
Merewether LA et al. Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. 2000 Arch. Biochem. Biophys. pmid:10683254
Ross FP RANKing the importance of measles virus in Paget's disease. 2000 J. Clin. Invest. pmid:10712423
Tricot G New insights into role of microenvironment in multiple myeloma. 2000 Lancet pmid:10675068
Chikatsu N et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. 2000 Biochem. Biophys. Res. Commun. pmid:10631114
Takami M et al. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. 2000 Endocrinology pmid:11108286
Gori F et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. 2000 Endocrinology pmid:11108292
Clohisy DR et al. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. 2000 J. Orthop. Res. pmid:11192258
Aubin JE and Bonnelye E Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. 2000 Osteoporos Int pmid:11193242
Wise GE et al. Osteoprotegerin and osteoclast differentiation factor in tooth eruption. 2000 J. Dent. Res. pmid:11201042
Kotake S et al. [Molecular mechanism of bone metabolism]. 2000 Nippon Naika Gakkai Zasshi pmid:11215116
Kanematsu M et al. [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. 2000 Biol. Sci. Space pmid:12561872
Saika M et al. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. 2001 Endocrinology pmid:11356664
Mackie PS et al. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. 2001 Br. J. Cancer pmid:11286476
Hofbauer LC et al. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. 2001 J. Rheumatol. pmid:11327234
Hofbauer LC and Heufelder AE The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. 2001 Arthritis Rheum. pmid:11229454
Leach RJ et al. The genetics of Paget's disease of the bone. 2001 J. Clin. Endocrinol. Metab. pmid:11231972
Luger NM et al. Osteoprotegerin diminishes advanced bone cancer pain. 2001 Cancer Res. pmid:11358823
Zhang J et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. 2001 J. Clin. Invest. pmid:11375413
Kostenuik PJ and Shalhoub V Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. 2001 Curr. Pharm. Des. pmid:11375772
Thirunavukkarasu K et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. 2001 J. Biol. Chem. pmid:11451955
Sasaki N et al. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. 2001 Nephrol. Dial. Transplant. pmid:11239019
Takeuchi T et al. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. 2001 Biochem. Pharmacol. pmid:11239501
Mori K et al. Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. 2001 Cell. Immunol. pmid:11243701
Hofbauer LC et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. 2001 Biochem. Biophys. Res. Commun. pmid:11162519
Brändström H et al. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. 2001 Biochem. Biophys. Res. Commun. pmid:11162596
Wuyts W et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. 2001 Bone pmid:11165949
Michigami T et al. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. 2001 Cancer Res. pmid:11245477
Wada N et al. Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. 2001 J. Periodont. Res. pmid:11246705
Jung K et al. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. 2001 Clin. Chem. pmid:11673385
Lean JM et al. FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. 2001 Blood pmid:11675341
Fiumara P et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. 2001 Blood pmid:11675352
Pearse RN et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11562486
Kostenuik PJ et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. 2001 Endocrinology pmid:11564687
Marco-Mingot M et al. Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. 2001 Clin. Genet. pmid:11531977
Raffai RL et al. Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11553788
Hocking LJ et al. Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. 2001 Am. J. Hum. Genet. pmid:11555792
Hofbauer LC et al. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. 2001 Cancer pmid:11505389
Hofbauer LC and Heufelder AE Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. 2001 J. Mol. Med. pmid:11485016
Furuya D et al. Immuno-PCR assay for homodimeric osteoprotegerin. 2001 Clin. Chem. pmid:11468243
Seck T et al. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. 2001 Eur. J. Endocrinol. pmid:11454517
Burguera B et al. Leptin reduces ovariectomy-induced bone loss in rats. 2001 Endocrinology pmid:11459801
Yamagishi T et al. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. 2001 Endocrinology pmid:11459812
Halladay DL et al. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. 2001 J. Cell. Biochem. pmid:11746511
Cao Y et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. 2001 Cell pmid:11747812
Chung H et al. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. 2001 J. Korean Med. Sci. pmid:11748360
Komuro H et al. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. 2001 Arthritis Rheum. pmid:11762937
Fukagawa M et al. [PTH and bone metabolism in chronic dialysis patients]. 2001 Rinsho Byori pmid:11307321
Horowitz MC et al. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. 2001 Cytokine Growth Factor Rev. pmid:11312114
Lin DL et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. 2001 Prostate pmid:11351351
Sparks AB et al. Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. 2001 Calcif. Tissue Int. pmid:11351498
Disthabanchong S and González EA Regulation of bone cell development and function: implication for renal osteodystrophy. 2001 J. Investig. Med. pmid:11352181
Kotake S et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. 2001 Arthritis Rheum. pmid:11352231

Table of Content